Uploaded December 2021 | Updated September 2026, 2 weeks ago
Register to upcoming events
everythingals.org/events
Participate in our ALS Research
everythingals.org/research
New Therapies for ALS
Dr. Merit Cudkowicz is the Chief of the Massachusetts General Hospital Neurology Service, Director, Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and the Julieanne Dorn Professor of Neurology at Harvard Medical School in Boston. Dr. Cudkowicz directs the Massachusetts General Hospital ALS Program. She is one of the founders and former co-directors of the Northeast ALS Consortium (NEALS), a group of over 135 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative academic-led clinical trials and research studies in ALS.
Dr. Cudkowicz is leading the first Platform Trial initiative in ALS. She is Principal Investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke’s Neurology Network of Excellence in Clinical Trials (NeuroNEXT). The NeuroNEXT network is an efficient phase II network to develop innovative and new treatments for people with neurological disorders.
DO NOT Miss Another Event, Subscribe to our Channel:
youtube.com/c/everythingals
Register to upcoming events
everythingals.org/events
Participate in our ALS Research
everythingals.org/research
New Therapies for ALS
Dr. Merit Cudkowicz is the Chief of the Massachusetts General Hospital Neurology Service, Director, Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and the Julieanne Dorn Professor of Neurology at Harvard Medical School in Boston. Dr. Cudkowicz directs the Massachusetts General Hospital ALS Program. She is one of the founders and former co-directors of the Northeast ALS Consortium (NEALS), a group of over 135 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative academic-led clinical trials and research studies in ALS.
Dr. Cudkowicz is leading the first Platform Trial initiative in ALS. She is Principal Investigator of the Clinical Coordination Center for the National Institute of Neurological Disorders and Stroke’s Neurology Network of Excellence in Clinical Trials (NeuroNEXT). The NeuroNEXT network is an efficient phase II network to develop innovative and new treatments for people with neurological disorders.
DO NOT Miss Another Event, Subscribe to our Channel:
youtube.com/c/everythingals
